Stocks and Investing
Stocks and Investing
Tue, November 9, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Marc Goodman Maintained (AXSM) at Buy with Decreased Target to $65 on, Nov 9th, 2021
Marc Goodman of SVB Leerink, Maintained "Axsome Therapeutics, Inc." (AXSM) at Buy with Decreased Target from $75 to $65 on, Nov 9th, 2021.
Marc has made no other calls on AXSM in the last 4 months.
There are 4 other peers that have a rating on AXSM. Out of the 4 peers that are also analyzing AXSM, 1 agrees with Marc's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Vikram Purohit of "Morgan Stanley" Downgraded from Buy to Hold and Decreased Target to $34 on, Tuesday, August 10th, 2021
These are the ratings of the 3 analyists that currently disagree with Marc
- Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $180 on, Monday, August 30th, 2021
- Vamil Divan of "Mizuho" Maintained at Strong Buy with Decreased Target to $55 on, Tuesday, August 10th, 2021
- Joon Lee of "Truist Securities" Maintained at Strong Buy with Decreased Target to $160 on, Tuesday, August 10th, 2021
Contributing Sources